This chart presents a detailed analysis of the 5-year relative survival rates for patients with various hematological malignancies, segmented by cancer type and diagnosis period. The data spans three periods: 2006-2010, 2011-2015, and 2016-2020. Notably, there is a general upward trend in survival rates across most cancer types over the years. Chronic lymphocytic leukemia, cutaneous T-cell lymphoma, and classic Hodgkin lymphoma show significant improvements, with survival rates reaching 89% by 2016-2020. In contrast, acute myeloid leukemia and T/NK-cell lymphoma have lower survival rates, though they have also seen some improvement over time. The overall survival rate for all hematological malignancies increased from 62% in 2006-2010 to 68% in 2016-2020. This data highlights the advancements in treatment and early diagnosis, contributing to better patient outcomes. However, the variation in survival rates among different cancer types underscores the need for continued research and targeted therapies.